AF
IKT icon

Allworth Financial’s Inhibikase Therapeutics IKT Stock Holding History

Allworth Financial’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$644 Buy
383
+382
+38,200% +$678 ﹤0.01% 4681
2025
Q4 		$3 Buy
+1
New +$2 ﹤0.01% 4994

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Allworth Financial's IKT Position: Q1 2026 in Review

Allworth Financial increased its Inhibikase Therapeutics (IKT) stake by 38,200% in Q1 2026, buying an estimated $678 and bringing the position to 383 shares worth $644. The position accounts for ﹤0.01% of the portfolio, ranked #4681.

Allworth Financial first reported a position in IKT in Q4 2025 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Allworth Financial held 383 shares of Inhibikase Therapeutics worth $644 as of Q1 2026.
  • Allworth Financial bought 382 Inhibikase Therapeutics shares in Q1 2026, an estimated $678.
  • Inhibikase Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4681 holding.
  • Allworth Financial first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.